Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...
Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their medical records for safety reasons, a move that comes as it builds a case ...
Eli Lilly is expanding the supply of its weight-loss drug and selling it for half the price of other drugs in the highly lucrative market. Eli Lilly announced on Tuesday that it is now offering ...
Eli Lilly is ramping up its campaign against imitations of its blockbuster appetite-suppressing drugs, seeking to put an end to a regulatory designation that has allowed cheaper, off-brand ...
Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...
Eli Lilly said it has started selling single-dose vials of its uber-popular weight-loss drug Zepbound as demand soars – and the smaller doses cost 50% less than rival drugs. The more affordable ...
Eli Lilly released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to increase ...
Eli Lilly will now sell cheaper vials of Zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the medication. By Dani Blum With high demand for drugs ...
Eli Lilly is announcing a new way to get its popular Zepbound drug. People who are in need of weight loss medications but do not have insurance coverage will soon have a new way to access one of ...
Eli Lilly & Co. LLY said Tuesday that patients can now access 2.5- and 5-milligram single-dose vials of its weight-loss treatment Zepbound with an on-label prescription at a discount of at least ...
Eli Lilly (NYSE: LLY) offers investors the same thing as many other big pharma companies: a certain level of security when it comes to revenue. Since people need their medicines regardless of the ...